Influences of the PPARα-L162V polymorphism on plasma HDL2-cholesterol response of abdominally obese men treated with gemfibrozil

被引：27

作者：

Bossé, Y

Pascot, A

Dumont, M

Brochu, M

Prud'homme, D

Bergeron, J

Després, JP

Vohl, MC

机构：

[1] CHUL, Res Ctr, Lipid Res Lab, St Foy, PQ G1V 4G2, Canada

[2] Univ Laval, Dept Social & Prevent Med, Kinesiol Div, Phys Act Sci Lab, Quebec City, PQ, Canada

[3] Univ Montreal, Dept Kinesiol, Montreal, PQ, Canada

[4] Univ Ottawa, Fac Hlth Sci, Ottawa, ON, Canada

[5] Univ Laval, Dept Food Sci & Nutr, Quebec City, PQ, Canada

[6] Quebec Heart Inst, Quebec City, PQ, Canada

来源：

GENETICS IN MEDICINE | 2002年 / 4卷 / 04期

关键词：

genetics; fibrates; lipid response; lipoproteins; high-density lipoprotein cholesterol;

D O I：

10.1097/00125817-200207000-00010

中图分类号：

Q3 [遗传学];

学科分类号：

071007 ; 090102 ;

摘要：

Purpose: The effect of gemfibrozil is mediated by the activation of peroxisome proliferator-activated receptor alpha (PPARalpha). The objective of this study was to determine whether the lipid response to gemfibrozil therapy is influenced by the PIPARalpha-L162V polymorphism. Methods: Sixty-three abdominally obese men were randomly assigned to a 6-month-intervention program with either receiving a placebo (N = 31) or gemfibrozil (N = 32). Results: In response to gemfibrozil therapy, L162-homozygotes exhibited a 5.5% increase in high-density lipoprotein 2 cholesterol (HDL2-C) levels compared with a 50.0% increase among carriers of the V162 allele (P = 0.03). Conclusion: These results suggest that the HDL2-C response to gemfibrozil is modulated by the PPARalpha-L162V polymorphism.

引用

页码：311 / 315

页数：5

共 20 条

[1] Opposite regulation of human versus mouse apolipoprotein A-I by fibrates in human apolipoprotein A-I transgenic mice [J].

Berthou, L ;

Duverger, N ;

Emmanuel, F ;

Langouet, S ;

Auwerx, J ;

Guillouzo, A ;

Fruchart, JC ;

Rubin, E ;

Denefle, P ;

Staels, B ;

Branellec, D .

JOURNAL OF CLINICAL INVESTIGATION, 1996, 97 (11) :2408-2416

[2] Induction of the phospholipid transfer protein gene accounts for the high density lipoprotein enlargement in mice treated with fenofibrate [J].

Bouly, M ;

Masson, D ;

Gross, B ;

Jiang, XC ;

Fievet, C ;

Castro, G ;

Tall, AR ;

Fruchart, JC ;

Staels, B ;

Lagrost, L ;

Luc, G .

JOURNAL OF BIOLOGICAL CHEMISTRY, 2001, 276 (28) :25841-25847

[3] CLA-1/SR-BI is expressed in atherosclerotic lesion macrophages and regulated by activators of peroxisome proliferator-activated receptors [J].

Chinetti, G ;

Gbaguidi, FG ;

Griglio, S ;

Mallat, Z ;

Antonucci, M ;

Poulain, P ;

Chapman, J ;

Fruchart, JC ;

Tedgui, A ;

Najib-Fruchart, J ;

Staels, B .

CIRCULATION, 2000, 101 (20) :2411-2417

[4] PPAR-α and PPAR-γ activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABCA1 pathway [J].

Chinetti, G ;

Lestavel, S ;

Bocher, V ;

Remaley, AT ;

Neve, B ;

Torra, IP ;

Teissier, E ;

Minnich, A ;

Jaye, M ;

Duverger, N ;

Brewer, HB ;

Fruchart, JC ;

Clavey, V ;

Staels, B .

NATURE MEDICINE, 2001, 7 (01) :53-58

[5] Effect of a six month gemfibrozil treatment and dietary recommendations on the metabolic risk profile of visceral obese men [J].

Dumont, M ;

Mauriège, P ;

Bergeron, J ;

Després, JP ;

Prud'homme, D .

INTERNATIONAL JOURNAL OF OBESITY, 2001, 25 (08) :1136-1143

[6] Variation in the PPARα gene is associated with altered function in vitro and plasma lipid concentrations in Type II diabetic subjects [J].

Flavell, DM ;

Torra, IP ;

Jamshidi, Y ;

Evans, D ;

Diamond, JR ;

Elkeles, RS ;

Bujac, SR ;

Miller, G ;

Talmud, PJ ;

Staels, B ;

Humphries, SE .

DIABETOLOGIA, 2000, 43 (05) :673-680

[7] HELSINKI HEART-STUDY - PRIMARY-PREVENTION TRIAL WITH GEMFIBROZIL IN MIDDLE-AGED MEN WITH DYSLIPIDEMIA - SAFETY OF TREATMENT, CHANGES IN RISK-FACTORS, AND INCIDENCE OF CORONARY HEART-DISEASE [J].

FRICK, MH ;

ELO, O ;

HAAPA, K ;

HEINONEN, OP ;

HEINSALMI, P ;

HELO, P ;

HUTTUNEN, JK ;

KAITANIEMI, P ;

KOSKINEN, P ;

MANNINEN, V ;

MAENPAA, H ;

MALKONEN, M ;

MANTTARI, M ;

NOROLA, S ;

PASTERNACK, A ;

PIKKARAINEN, J ;

ROMO, M ;

SJOBLOM, T ;

NIKKILA, EA .

NEW ENGLAND JOURNAL OF MEDICINE, 1987, 317 (20) :1237-1245

[8]

GIDEZ LI, 1982, J LIPID RES, V23, P1206

[9] HIGH-DENSITY-LIPOPROTEINS AND CORONARY ATHEROSCLEROSIS - A STRONG INVERSE RELATION WITH THE LARGEST PARTICLES IS CONFINED TO NORMOTRIGLYCERIDEMIC PATIENTS [J].

JOHANSSON, J ;

CARLSON, LA ;

LANDOU, C ;

HAMSTEN, A .

ARTERIOSCLEROSIS AND THROMBOSIS, 1991, 11 (01) :174-182

[10]

Lacquemant C, 2000, DIABETES METAB, V26, P393

← 1 2 →